National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Co, Dublin, Ireland.
Thermo Fisher Scientific, Stafford House, Hemel Hempstead, UK.
Crit Rev Anal Chem. 2024;54(8):3234-3251. doi: 10.1080/10408347.2023.2238058. Epub 2023 Jul 25.
The rapid growth of biotherapeutic industry, with more and more complex molecules entering the market, forces the need for advanced analytical platforms that can quickly and accurately identify and quantify product quality attributes. Mass spectrometry has the potential to provide more detailed information about the quality attributes of complex products, and MS methods are more sensitive than UV methods for detection of impurities. The multi-attribute method (MAM), a liquid chromatography-mass spectrometry based analytical approach is an emerging platform which supports biotherapeutic characterization and cGMP testing. The main advantage lies in the ability to monitor multiple quality attributes in a single assay, both at the peptide and the intact level, facilitating streamlined biopharmaceutical production, from research and development to the QC environment. This review highlights the current landscape of the MAM approach with special attention given to increased analytical throughput, general requirements for QC in terms of instrumentation and software, regulatory requirements, and industry acceptance of the MAM platform.
生物治疗行业的快速发展,使得越来越多复杂的分子进入市场,这就迫使我们需要先进的分析平台,以便能够快速、准确地识别和定量产品的质量属性。质谱法有可能提供关于复杂产品质量属性的更详细信息,并且对于杂质的检测,MS 方法比 UV 方法更灵敏。多属性方法(MAM)是一种基于液相色谱-质谱的分析方法,是一种新兴的平台,支持生物治疗特性和 cGMP 测试。其主要优势在于能够在单个测定中同时监测多个质量属性,包括肽和完整水平,从而促进生物制药生产的简化,从研发到 QC 环境。本综述重点介绍了 MAM 方法的现状,特别关注分析通量的提高、QC 对仪器和软件的一般要求、监管要求以及行业对 MAM 平台的接受程度。